Is This Another Strike Against Biogen's Alzheimer's Drug?

A crucial moment for biotech giant Biogen (NASDAQ: BIIB) is only two months away. The U.S. Food and Drug Administration will decide whether to approve aducanumab, an investigational Alzheimer's treatment. Late last year, an FDA advisory panel advised regulators to give the candidate the thumbs-down.

A spark of hope came weeks later: The FDA said it needed more time to make its decision. Then, just last week, three members of the FDA advisory panel wrote a piece in The Journal of the American Medical Association (JAMA) reiterating their negative views on aducanumab. Is this another strike against Biogen's prospects? Let's take a closer look.

Image source: Getty Images.

Continue reading

Source Fool.com